W. Chin

发表

Innovation in Development, Regulatory Review, and Use of Clinical Advances: A Vital Direction for Health and Health Care

Sachin H. Jain, C. Austin, J. Woodcock, 2016 .

A Call for Sharing: Adapting Pharmaceutical Research to New Realities

B. Munos, W. Chin, 2009, Science Translational Medicine.

Broader Transparency on Risk-benefit Assessment of the Bial Trial in France

W. Chin, 2016 .

Moving toward a paradigm shift in the regulatory requirements for pediatric medicines

W. Chin, A. Joos, 2016, European Journal of Pediatrics.

Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery

Sam Michael, Anton Simeonov, Menghang Xia, 2018, Clinical and translational science.

How to Revive Breakthrough Innovation in the Pharmaceutical Industry

Bernard H. Munos, B. Munos, W. Chin, 2011, Science Translational Medicine.

What evidence do we need for biomarker qualification?

Chris Leptak, Joseph P Menetski, John A Wagner, 2017, Science Translational Medicine.

Preclinical efficacy studies in investigator brochures: Do they enable risk–benefit assessment?

D. Strech, J. Kimmelman, W. Chin, 2018, PLoS biology.

The Human Touch - Addressing Health Care's Workforce Problem amid the Pandemic.

W. Chin, Eli M. Cahan, L. B. Levine, 2020, The New England journal of medicine.

Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross‐sectional study

Daniel Strech, Holger Langhof, Carole Federico, 2018, British journal of pharmacology.